{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marrugal-Lorenzo JA"],"funding":["Universidad de Sevilla","Universidad de Sevilla (University of Seville)"],"pagination":["17"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6327057"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["The repositioning of drugs already approved by regulatory agencies for other indications is an emerging alternative for the development of new antimicrobial therapies. The repositioning process involves lower risks and costs than the de novo development of novel antimicrobial drugs. Currently, infections by adenovirus show a steady increment with a high clinical impact in immunosuppressed and immunocompetent patients. The lack of a safe and efficacious drug to treat these infections supports the search for new antiviral drugs. Here we evaluated the anti-adenovirus activity of niclosanide, oxyclozanide, and rafoxanide, three salicylanilide anthelmintic drugs. Also, we carried out the cytotoxicity evaluation and partial characterization of the mechanism of action of these drugs. The salicyla"],"journal":["Scientific reports"],"pubmed_title":["Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections."],"pmcid":["PMC6327057"],"funding_grant_id":["USE-16591-P"],"pubmed_authors":["Serna-Gallego A","Marrugal-Lorenzo JA","Sanchez-Cespedes J","Pachon J","Berastegui-Cabrera J"],"additional_accession":[]},"is_claimable":false,"name":"Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.","description":"The repositioning of drugs already approved by regulatory agencies for other indications is an emerging alternative for the development of new antimicrobial therapies. The repositioning process involves lower risks and costs than the de novo development of novel antimicrobial drugs. Currently, infections by adenovirus show a steady increment with a high clinical impact in immunosuppressed and immunocompetent patients. The lack of a safe and efficacious drug to treat these infections supports the search for new antiviral drugs. Here we evaluated the anti-adenovirus activity of niclosanide, oxyclozanide, and rafoxanide, three salicylanilide anthelmintic drugs. Also, we carried out the cytotoxicity evaluation and partial characterization of the mechanism of action of these drugs. The salicyla","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-22T07:38:39.474Z","creation":"2019-03-26T22:36:27Z"},"accession":"S-EPMC6327057","cross_references":{"pubmed":["30626902"],"doi":["10.1038/s41598-018-37290-3"]}}